Treatment Options for Sickle Cell Anemia and Asthma: Medications, Transfusions, and Inhalers
Two distinct chronic conditions with overlapping pulmonary complications.
Sickle Cell Disease (SCD) – HbSS
Disease-Modifying
- Hydroxyurea: ↑ HbF → ↓ sickling; reduces VOC, ACS, transfusion need. Standard of care from 9 months.
- Voxelotor: HbS polymerization inhibitor; ↑ Hb, ↓ hemolysis.
- Crizanlizumab: P-selectin inhibitor; ↓ VOC frequency.
- L-glutamine: Reduces oxidative stress; ↓ VOC.
Curative
- Allogeneic HCT: Matched sibling donor best; >90% cure if <16 yrs. Gene therapy (lentiviral β-globin) emerging.
Supportive
- Chronic transfusions (stroke prevention, TCD velocities).
- Iron chelation (deferasirox, deferoxamine).
- Penicillin prophylaxis <5 yrs; pneumococcal/meningococcal/Hib vaccines.
- Pain management (opioids, adjuvants, non-pharm).
Asthma
Controller Therapy (Stepwise)
| Step | Preferred Controller |
|---|---|
| 1 | SABA PRN (intermittent) |
| 2 | Low-dose ICS |
| 3 | Low-dose ICS-LABA |
| 4 | Medium-dose ICS-LABA |
| 5 | High-dose ICS-LABA + LAMA ± biologics |